Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 03, 2013 21:45 ET | Source: Prima BioMed

CVac(TM) CAN-003 Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting

SYDNEY, AUSTRALIA--(Marketwired - Sep 3, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today announced that the abstract entitled, "Study of...
August 20, 2013 20:00 ET | Source: Prima BioMed

Prima BioMed to Present at the 15th Annual Rodman & Renshaw Global Investment Conference

SYDNEY, AUSTRALIA--(Marketwired - Aug 20, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") has announced today that Matthew Lehman, its Chief...
August 14, 2013 07:10 ET | Source: Prima BioMed

Prima BioMed's "CANVAS" Clinical Trial Approved to Start in Korea

SYDNEY, AUSTRALIA--(Marketwired - Aug 14, 2013) - Prima BioMed Ltd (ASX: PRR); (NASDAQ: PBMD); (ISIN: US74154B2034) ("Prima", the "Company") is pleased to announce that the Korean Ministry of Food...
July 25, 2013 20:50 ET | Source: Prima BioMed

Prima BioMed Fourth Quarter Highlights and Conference Call

SYDNEY, AUSTRALIA--(Marketwired - Jul 25, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today released its Appendix 4C - Quarterly Report for the...
July 03, 2013 19:15 ET | Source: Prima BioMed

Prima BioMed Activates Study Sites in Germany and Multiple European Countries for "CANVAS" Clinical Trial

SYDNEY, AUSTRALIA--(Marketwired - Jul 3, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") is pleased to announce that it has activated a...
June 24, 2013 20:00 ET | Source: Prima BioMed

Prima BioMed to Move Forward With Phase 2 Clinical Program for CVac(TM) in Pancreatic, Colorectal, and Triple-Negative Breast Cancers

SYDNEY, AUSTRALIA--(Marketwired - Jun 24, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") today announced that it will move forward with three...
June 19, 2013 19:05 ET | Source: Prima BioMed

CVac(TM) CAN-003 Trial Selected for Oral Presentation at the European Cancer Congress

SYDNEY, AUSTRALIA--(Marketwired - Jun 19, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") today announced that the abstract titled "Clinical study...
May 20, 2013 07:35 ET | Source: Prima BioMed

Prima BioMed to Present at the Second Annual Marcum LLP MicroCap Conference

SYDNEY, AUSTRALIA--(Marketwired - May 20, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," the "Company") has announced today that Matthew Lehman, its Chief...
May 16, 2013 22:35 ET | Source: Prima BioMed

Prima BioMed Issues the Following Notice to Stockholders of the Company

SYDNEY, AUSTRALIA--(Marketwired - May 16, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") has announced in pursuant to shareholder approval received...
May 07, 2013 22:15 ET | Source: Prima BioMed

Russell J. Howard to Join Prima BioMed's Board of Directors

SYDNEY, AUSTRALIA--(Marketwired - May 7, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", the "Company") is pleased to announce that Russell J. Howard, PhD, will...